{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:59:28Z","timestamp":1792645168165,"version":"4.5.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Toripalimab in combination with cisplatin and paclitaxel is indicated as a first-line treatment for metastatic esophageal squamous cell carcinoma (ESCC). Toripalimab, a PD-1 inhibitor, commonly causes immune-related adverse reactions such as immune-related rash, immune-related pneumonitis, and immune-related diarrhea and colitis. This study reports a case of toripalimab-induced exacerbation of psoriasis in an esophageal cancer patient, emphasizing the need for careful monitoring and management in such treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 60-year-old male patient with a history of well-controlled psoriasis without medication and no other significant medical conditions was hospitalized due to recurrence and exacerbation of psoriasis following two cycles of Toripalimab combined with cisplatin and nab-paclitaxel therapy after esophageal malignancy surgery. The psoriasis flare-up was considered to be induced by Toripalimab. After admission, the patient was treated with high-dose methylprednisolone. Upon symptom control, the steroid dosage was gradually tapered and completely discontinued over a total course of approximately eight weeks, with no recurrence throughout the tapering and discontinuation period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>For cancer patients with pre-existing autoimmune diseases, particularly those with psoriasis, comprehensive multidisciplinary evaluation is essential before initiating Toripalimab therapy. During immunotherapy cycles, specialized follow-up by dermatologists and clinical pharmacists is recommended to monitor the status of pre-existing dermatological conditions and potential adverse reactions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1596818","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T04:13:42Z","timestamp":1756268022000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Toripalimab induces exacerbation of psoriasis in an esophageal cancer patient: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Luping","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piaopiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"B1","unstructured":"Toripalimab, the first domestic anti-PD-1 monoclonal antibody, was approved into market\n          \n          2018"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01076-2","article-title":"Toripalimab: first global approval","volume":"79","author":"Keam","year":"2019","journal-title":"DRUGS"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730666","article-title":"Toripalimab: the first domestic anti-tumor PD-1 antibody in China","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"2015","author":"Boehncke","year":"9997","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J Eur Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/PTT.S126727","article-title":"Drug-induced psoriasis: clinical perspectives","volume":"7","author":"Balak","year":"2017","journal-title":"Psoriasis (Auckl)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20809","article-title":"Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance","volume":"6","author":"Papp","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J Immunother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20211221-02842","article-title":"Multidisciplinary Diagnosis and Treatment Professional Committee of Chinese Medical Doctor Association. Recommendations for prevention and management of immune checkpoint inhibitor-related toxicities","volume":"102","year":"2022","journal-title":"Natl Med J China"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e14830","DOI":"10.1111\/dth.14830","article-title":"Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors","volume":"34","author":"Cutroneo","year":"2021","journal-title":"Dermatol Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e15703","DOI":"10.7759\/cureus.15703","article-title":"A case of de novo psoriasis secondary to nivolumab in a patient with metastatic renal cell carcinoma","volume":"13","author":"Mullangi","year":"2021","journal-title":"Cureus"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e5824","DOI":"10.7759\/cureus.5824","article-title":"Novel approach to the treatment of pembrolizumab-induced psoriasis exacerbation: A case report","volume":"11","author":"Monsour","year":"2019","journal-title":"Cureus"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.03.015","article-title":"Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series","volume":"11","author":"Mayor Ibarguren","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-024-01494-4","article-title":"Clinical features, treatment, and outcomes of nivolumab induced psoriasis","author":"Zhao","year":"2023","journal-title":"Invest New Drug"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e48453","DOI":"10.7759\/cureus.48453","article-title":"New-onset psoriasis induced by durvalumab","volume":"15","author":"Shoukfeh","year":"2023","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.579445","article-title":"Pembrolizumab-induced psoriasis in metastatic melanoma: activity and safety of apremilast, a case report","volume":"10","author":"Siciliano","year":"2020","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60030373","article-title":"Perspectives on psoriasiform adverse events from immune checkpoint inhibitors: lessons learned from our practice","volume":"60","author":"Popa","year":"2023","journal-title":"MEDICINA-LITHUANIA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jaad.2022.02.030","article-title":"Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review","volume":"87","author":"Said","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S534032","article-title":"Tobacco Smoking Was Positively Associated with Disease Relapse at week 24 and 48 Among Patients with Psoriasis Vulgaris in Shanghai: A Prospective Study","volume":"15","author":"Shen","year":"2025","journal-title":"Psoriasis (Auckl)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae130","article-title":"Effect of smoking cessation on psoriasis vulgaris, palmoplantar pustulosis and generalized pustular psoriasis","volume":"191","author":"Kim","year":"2024","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15380","article-title":"Dose-response analysis between alcohol consumption and psoriasis: A systematic review and meta-analysis","volume":"22","author":"Choi","year":"2024","journal-title":"J der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatology: JDDG vol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0296844","article-title":"Encapsulated Streptococcus suis impairs optimal neutrophil functions which are not rescued by priming with colony-stimulating factors","volume":"19","author":"Bleuz\u00e9","year":"2024","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4046\/trd.2023.0037","article-title":"Immune evasion of G-CSF and GM-CSF in lung cancer","volume":"87","author":"Park","year":"2024","journal-title":"Tuberculosis Respir Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00281-015-0539-8","article-title":"Update on psoriasis immunopathogenesis and targeted immunotherapy","volume":"38","author":"Mahil","year":"2016","journal-title":"Semin Immunopathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2023.09.003","article-title":"Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors","volume":"99","author":"Wan","year":"2024","journal-title":"Anais brasileiros dermatologia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010088","article-title":"Immune checkpoint inhibitor-associated cutaneous adverse events: mechanisms of occurrence","volume":"26","author":"Eshaq","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3892\/etm.2023.11976","article-title":"Study of dietary\u2212induced progression of psoriasis\u2212like mice based on gut macrophage polarization","volume":"25","author":"Zeng","year":"2023","journal-title":"Exp Ther Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1286344","article-title":"Crosstalk: keratinocytes and immune cells in psoriasis","volume":"14","author":"Kamata","year":"2023","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41423-023-00973-7","article-title":"FXYD3 enhances IL-17A signaling to promote psoriasis by competitively binding TRAF3 in keratinocytes","volume":"20","author":"Yang","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2212","article-title":"Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma","volume":"96","author":"Matsumura","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-01308-2","article-title":"Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6","volume":"3","author":"Tanaka","year":"2020","journal-title":"Commun Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1346687","article-title":"Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors","volume":"15","author":"Morelli","year":"2023","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.140825","article-title":"Cannabidiol-loaded hydrogel microneedle patches inhibit TRIM14\/TRAF3\/NF-\u03baB axis for the treatment of psoriasis","volume":"304","author":"Li","year":"2025","journal-title":"Int J Biol macromolecules"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110328","article-title":"IL-17A\/F double producing T cells, unstable Tregs and quiescent TRMs in clinically healed lesions are potential cellular candidates for recurrence of psoriasis","volume":"266","author":"Peng","year":"2024","journal-title":"Clin Immunol (Orlando Fla.)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiae254","article-title":"Unveiling the role of resident memory T cells in psoriasis","volume":"117","author":"Saavedra-Almarza","year":"2025","journal-title":"J leukocyte Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00262-024-03635-3","article-title":"Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells","volume":"73","author":"Rajasekaran","year":"2024","journal-title":"Cancer immunology immunotherapy: CII"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12025\/j.issn.1008-6358.2025.20250020","article-title":"Expert Committee of Multi-disciplinary expert consensus on cutaneous adverse events caused by immune checkpoint inhibitors. Multi-disciplinary expert consensus on cutaneous adverse events caused by immune checkpoint inhibitors","volume":"32","author":"Sun","year":"2025","journal-title":"Chin J Clin Med"},{"key":"B41","article-title":"Clinical practice guideline: immune checkpoint inhibitor toxicity management","year":"2018","journal-title":"Cancer Care Ontario"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1596818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T04:13:46Z","timestamp":1756268026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1596818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":42,"alternative-id":["10.3389\/fonc.2025.1596818"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1596818","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"article-number":"1596818"}}